ECP effective in the long-term

Article

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Endoscopic cyclophotocoagulation (ECP) is an effective approach for the long-term management of difficult glaucoma cases and should be considered as a first-line treatment for refractory glaucoma, according to Francisco Lima, MD speaking at the "Surgery & Lasers in Glaucoma" session.

Dr Lima and colleagues conducted a long-term retrospective study of ECP in refractory glaucomas that included 539 eyes of 485 patients. Each subject underwent one ECP and were followed-up for a minimum five-year period, and retrospectively reviewed. Limbal or pars plana ECP was performed for 210 degrees with scleral depression of the ciliary body.Preoperative IOP was 37.9±6.4 mmHg, diminishing to 15.7±8.5 mmHg. The average number of surgeries preoperatively was 2.2 and the mean number of preoperative medications was 3.9±0.6, reducing postoperatively to 1.5±1.1. Success at one and five years postoperatively (defined as IOP between 5 and 22 mmHg) was 92.6% and 78.8%, respectively. Complications included fibrin exudates (21.5%), failed corneal graft (19.7%), hyphaema (10.7%), immediate postoperative IOP spike (9.8%), choroidal detachment (5.8%), phthisis (2.4%), retinal detachment (1.5%) and hypotony (1.3%).

The authors of this study believe that the results demonstrate the effectiveness of ECP as a long-term management approach for refractory glaucoma and recommend that it be considered as a first-line treatment.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.